From Viral Architecture to Clinical Impact: Defining the Next Era of HIV Treatment

Phase 3 data show DOR/ISL matches standard INSTI-based therapy in efficacy and safety, signaling a potential shift in first-line HIV treatment.

Two-year data confirm DOR/ISL delivers durable viral suppression—even in patients with high viral loads or advanced disease.

DOR/ISL exemplifies how 2-drug regimens could meet the complex needs of an aging HIV population.

Real-world data suggest long-acting injectables may help achieve—not just maintain—viral suppression.

Long-acting CAB+RPV may maintain efficacy even with delayed injections, offering real-world flexibility.

Long-acting therapies could be key to engaging unsuppressed patients and closing persistent gaps in HIV care.